SecBot SecBot
Biotech Drug Report Generated Nov 16, 2026

MGD024

MGNX·MACROGENICS INC
NEUTRAL
Drug Impact Rating3/10
Trial phase
Phase 1
Time to market
MGD024 is in Phase 1 testing with no disclosed timeline for Phase 2 or registrational studies. Approval, if successful, is likely several years away (5+ years under typical development timelines).
Why 3/10
MGD024 is an early Phase 1 program with no scheduled near-term binary catalyst. The company's next hard catalyst is MGC026 data mid-2027, not MGD024. MGD024 is one of several pipeline assets at MacroGenics and not the lead program. Per the rubric, an early-stage drug with no pending regulatory decision and no dated catalyst within ~12 months scores a 3.
Actionable Insight NEUTRAL

MGD024 has no near-term binary catalyst, so it is unlikely to drive a significant stock move in the next 12 months on its own. Investors should watch for any Phase 1 data readout or Gilead option exercise on MGD024 specifically, but the company's near-term value inflection points are tied to MGC026 (data mid-2027) and lorigerlimab enrollment progress. MacroGenics' cash runway through 2028 reduces dilution risk but does not eliminate it.

Price Chart

Loading chart...

Executive Summary

MGD024 is an investigational CD123xCD3 bispecific T-cell engager being developed by MacroGenics (MGNX) in collaboration with Gilead Sciences under a 2022 deal worth up to $1.76 billion in milestones. It is in Phase 1 testing for blood cancers. The program is early-stage and represents one of several pipeline assets at MacroGenics, which is currently prioritizing its B7-H3 ADC MGC026. No specific MGD024 data or near-term catalyst has been disclosed, and the stock's value is driven more by other pipeline programs and the company's cash position ($288M as of Q3 2026).

How It Works

MGD024 is a bispecific antibody built on MacroGenics' DART platform. It has two arms: one grabs CD123 (a protein found on the surface of certain blood cancer cells like leukemia) and the other grabs CD3 (a protein on immune T-cells). By binding both at once, it forces the immune system's T-cells to attack and kill the CD123-positive cancer cells. This is called a T-cell engager approach.

Trial Status

MGD024 is being studied in a Phase 1, first-in-human clinical trial for blood cancers (CD123-positive hematologic malignancies such as acute myeloid leukemia). The trial was noted as ongoing as of late 2025. MacroGenics' most recent corporate presentation (November 2026) still lists MGD024 in its pipeline, but the company has not disclosed specific enrollment updates or interim data for this program in recent quarters.

The Two-Sided Case

▲ Bull Case4
Gilead partnership provides validation and non-dilutive funding: Gilead paid $60M upfront in 2022 and exercised a separate option on another MacroGenics bispecific program in August 2026, signaling continued partnership interest. The deal includes up to $1.76B in milestones plus tiered royalties.
CD123xCD3 bispecific T-cell engagers are a clinically validated modality; approved drugs like blinatumomab (CD19xCD3) have established the T-cell engager mechanism in hematologic cancers.
MacroGenics has $288M cash with runway through 2028, reducing near-term financing risk for early-stage programs like MGD024.
Analyst consensus is bullish on MGNX overall: 9 buy/strong buy ratings vs 5 hold and 0 sell, with a mean price target of $8 (264% upside from the $2.20 close).
▼ Bear Case5
MGD024 is in very early Phase 1 testing with no disclosed efficacy or safety data; most early-stage oncology assets fail to reach approval.
The CD123xCD3 bispecific space is competitive, with multiple programs from larger players (e.g., Pfizer's vibecotamab, Jazz/GRAIL programs) already in development.
MacroGenics has no approved products and is pre-revenue; the stock trades at $2.20 with a market cap of ~$148M, reflecting pipeline risk.
The company's recent Q3 2026 earnings missed revenue estimates, and the focus has shifted to other pipeline programs (MGC026, MGC028, lorigerlimab), with no MGD024-specific updates in recent quarters.
Several institutional holders trimmed or exited positions in Q3 2026, and the bull/bear case tool shows a net bearish signal over the last 90 days.

Upcoming Catalysts

  • No specific near-term catalyst for MGD024 has been disclosed. The next company-wide pipeline catalyst is MGC026 data update expected mid-2027.

Source Filing

The SecBot filing or press-release report that triggered this drug report:

MACROGENICS INC 8-K MGNX ·Originating report

Sources · 7

Hover a chip for the title
1 businesswire.com2 pharmaphorum.com3 theglobeandmail.com4 manilatimes.net5 markets.businessinsider.com6 sec.gov7 medcitynews.com